Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2019-03-06 Capital/Financing Update
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. on March 6, 2019. It registers additional common shares reserved for issuance under the company's 2014 Equity Incentive Plan. The document includes details about the securities to be registered, incorporation by reference of prior filings including the company's Annual Report on Form 10-K, and exhibits such as the equity incentive plan and share option agreements. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital market filing related to the registration of securities for issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (over 10,000 characters) and contains detailed registration information, not just an announcement or reference to a report, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2019-03-06 English
10-K
Annual Report FY 2018
2019-03-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2019, by Xenon Pharmaceuticals Inc. It announces the company's financial results for the year ended December 31, 2018, via a press release attached as Exhibit 99.1. The text explicitly states that the information and the press release are furnished but not filed with the SEC, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3175 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2019-03-06 English
AMENDMENT NO. 7 TO THE SCHEDULE 13G
Major Shareholding Notification
2019-02-14 English
SCHEDULE 13G/A
Major Shareholding Notification
2019-02-14 English
XENON PHARMACEUTICALS, INC.
Major Shareholding Notification
2019-02-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.